You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1586 Results
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Dec 2024
Regimen
Cancer Type:
Gynecologic, 
Cervix, 
Endometrial, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Dec 2024
Regimen
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Dec 2024
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Jan 2025
Le Comité directeur de l’Ontario pour les médicaments contre le cancer (CDOMC) a été constitué en 2013 pour élargir et soutenir l’administration des...
Senior Scientist, Indigenous Cancer Care Unit, Acute and Hospital-Based Care, Ontario Health Lead Scientist amanda.sheppard@ontariohealth.ca
Senior chercheuse, Unité des soins de cancérologie chez les peuples autochtones, Soins aigus et hospitaliers, Santé Ontario Chercheuse...
Senior Scientist, Acute and Hospital-Based Care, Ontario Health Senior Scientistanna.chiarelli@ontariohealth.ca
Chercheuse principale, Soins aigus et hospitaliers, Santé Ontario Chercheuse principaleanna.chiarelli@ontariohealth.ca
Drug
Other Name(s): Kyprolis®
Feb 2024
Document

Pages